Immune checkpoint inhibitors are revolutionizing cancer treatment for many patients,
alongside surgery, chemotherapy and radiotherapy.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Side effects of immunotherapy: a constant challenge for oncologists.Curr Opin Oncol. 2019; 31: 280-285
- Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines.Asia Pac J Oncol Nurs. 2019 Apr-Jun; 6: 154-160
- Advances in targeting Co-inhibitory and Co-stimulatory pathways in transplantation settings: the yin to the yang of cancer immunotherapy.Immunol Rev. 2017 Mar; 276: 192-212
- Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?.Eur J Canc. 2019 Nov; 122: 72-901
- Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma.Exp Hematol Oncol. Published online. 2012 Mar 26; 1: 3
- Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab.Anti Canc Drugs. 2017 Aug; 28: 811-814
- Ipilimumab-induced neutropenia in melanoma.J Investig Med High Impact Case Rep. 2016 Jul-Sep; 42324709616661835
- Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab – case report.Oncol Res Treat. 2015; 38: 105-108
- Serious haematological toxicity during and after ipilimumab treatment: a case series.J Med Case Rep. 2014 Jul 1; 8: 240
- A case of severe Pembrolizumab-induced neutropenia.Anti Canc Drugs. 2018 Sep; 29: 817-819
Article info
Publication history
Published online: March 17, 2020
Accepted:
February 9,
2020
Received:
December 9,
2019
Identification
Copyright
© 2020 Elsevier Ltd. All rights reserved.
